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Background. Anal cancer is caused by human papillomavirus (HPV), yet little is known about anal HPV infection among healthy young women.
Methods. A total of 2017 sexually active women in the control arm of an HPV-16/18 vaccine trial had a single anal specimen collected by a clinician at the 4-year study visit. Samples were tested for HPV by SPF 10 PCR/ DEIA/LiPA 25 , version 1.
Results. A total of 4% of women had HPV-16, 22% had oncogenic HPV, and 31% had any HPV detected in an anal specimen. The prevalence of anal HPV was higher among women who reported anal intercourse, compared with those who did not (43.4% vs 28.4%; P < .001). Among women who reported anal intercourse, cervical HPV (adjusted odds ratio [ Conclusion. Anal HPV is common among young women, even those who report no anal sex, and was associated with cervical HPV infection. Anal fissures in women who report never having had anal intercourse may facilitate HPV exposure.
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Anal cancer is rare, with age-standardized annual incidence rates of 0.2-1.4 cases/100 000. Rates are higher in women and vary by geographical location [1] . During the past 3-4 decades, a significant increase in anal cancer rates has been reported for both sexes in many developed countries [2] [3] [4] . Several epidemiological studies suggest that oncogenic human papillomavirus (HPV) infection, a necessary cause of cervical cancer, is the main cause of anal cancer and its precursor lesions [5] [6] [7] [8] [9] . A recent metaanalysis [10] of 29 anal cancer studies estimated that HPV DNA was present in 84% of anal cancers worldwide and confirmed previous observations that HPV -16 was the most frequent genotype associated with anal carcinoma (>75% of cases), followed by HPV-18 and HPV-33 (approximately 10% of cases combined).
Research on the natural history of anal HPV infection suggests that sexual behavior is the main risk factor [11] [12] [13] [14] [15] [16] . However, the majority of the research to date has focused on high-risk groups, such as men who have sex with men (MSM) or human immunodeficiency virus-infected male and female subjects. Thus, little is known about anal HPV infection in healthy women. Only one prospective study, which occurred in Hawaii [16] , investigated anal HPV infection among healthy women (age range, 18-55 years). The overall prevalence of anal HPV infection was 27%. During follow-up, the vast majority (approximately 90%) of infections cleared by 1 year [17] . The epidemiology of anal HPV infections might vary by age, geographical location, and other characteristics; thus, additional epidemiological studies are warranted to better understand the natural history of anal HPV infection in other general populations. The aim of the present study was to estimate prevalence of individual anal HPV types in young healthy women in Costa Rica and to characterize risk factors for anal HPV infection in this group.
METHODS

Subject Participants and Study Design
Women included in the present evaluation are participants from the control arm of a double-blind, controlled, randomized, phase III study of the efficacy of an HPV-16/18 virus-like particle vaccine in Costa Rica (the Costa Rica Vaccine Trial [CVT]), which has been previously described [18] . Enrolled women from Guanacaste and selected areas of Puntarenas were identified via a census conducted between 2004 and 2005. The main eligibility requirements were as follows: age, 18-25 years (inclusive); good health, determined by history and a physical examination; and willingness to provide written informed consent. The trial was reviewed and approved by human subjects review committees of Instituto Costarriciense de Investigacion y Ensenanza en Nutricion y Salud (INCIEN-SA), in Costa Rica, and the National Cancer Institute (NCI), in the United States.
A total of 7466 women were recruited for the trial, randomized to receive 3 doses of the HPV vaccine or a control hepatitis A virus vaccine over a 6-month period, and followed annually, with additional visits if clinically indicated [18] . At all study visits, cervical specimens were collected in PreservCyt from sexually experienced women.
At the 4-year annual study visit, women who reported to be sexually active (defined as having had vaginal intercourse) were invited to provide an anal specimen for the evaluation of the HPV vaccine's efficacy against anal HPV infection. To study the epidemiology of anal HPV infection, analyses in the present study were restricted only to women enrolled in the control arm of the trial.
First, a questionnaire including questions about education, marital status, sexual (including anal intercourse) and reproductive history, use of contraceptives, smoking habits, and family history of cancer was administered. Additionally, among monogamous women, information related to their sex partner, including age, education, circumcision, sexual history, and smoking status, was obtained. Then, a complete medical history was obtained, and a physical examination that included anal specimen collection and a pelvic examination (with cervical specimen collection) were conducted.
Specimen Collection
The anal specimen was collected prior to the pelvic examination by inserting a dry swab 3-4 cm into the anal canal, rotating the swab 1 time, and removing the swab while continuing the rotation, using gentle pressure against the wall of the anal canal. The swab was placed in 1 mL of PreservCyt and frozen immediately in liquid nitrogen.
HPV DNA Testing
Cervical and anal specimens were tested using broad-spectrum polymerase chain reaction (PCR)-based HPV DNA testing at DDL Diagnostic Laboratory in the Netherlands, using SPF 10 PCR/DEIA/LiPA 25 , version 1 (Lab Biomedical Products, Rijswijk, the Netherlands), which is based on amplification of the viral L1 gene using the SPF10 primers. All samples were run through an HPV DNA enzyme immunoassay (DEIA), and the DEIA-positive samples were genotyped by the LiPA line detection system, as described elsewhere [19] [20] [21] . All specimens positive for HPV DNA by means of the SPF10 DEIA were additionally tested for the presence of HPV-16 and HPV-18 DNA, using type-specific primers [19, 22] .
Statistical Analysis
An anal sample was considered positive for any HPV genotype if it was positive for ≥1 of 25 HPV types. A sample was considered positive for oncogenic HPV if any of 13 oncogenic HPV types (ie, type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68/73) were detected [23] , regardless of the presence of nononcogenic HPV. In contrast, a sample was considered positive for a nononcogenic HPV type if only a nononcogenic HPV type (ie, type 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, and 74) was detected in the absence of an oncogenic type. A sample that was SPF 10 DEIA-positive, but LiPA25 negative was considered as uncharacterized HPV. For cervical HPV status, a sample was defined as positive for any HPV type if it tested positive for ≥1 of 25 HPV types, regardless of other HPV infections. The distribution of anal HPV was described overall and by the above categorizations.
Determinants for anal HPV infection were evaluated by logistic regression analysis. Variables evaluated in univariate modeling included age, education, marital status, number of pregnancies, age at first sexual intercourse, lifetime number of sex partners, number of sex partners since the last study visit (a proxy for recent sexual behavior), frequency of condom use, history of anal intercourse, age at first anal intercourse, number of lifetime anal intercourse partners, use of oral contraceptives, and smoking status. Self-reported anal medical conditions (anal hemorrhage, hemorrhoids, and anal fissure) were also evaluated.
To understand the contribution of cervical HPV infection to anal HPV infection, concurrent cervical HPV DNA status (measured at the same time as the anal specimen was collected), and persistent cervical HPV DNA status (measured 2 times: at the concurrent visit and the visit immediately preceding anal specimen collection, which occurred a median of 15 months [range, 1-58 months] earlier) were evaluated.
Odd ratios (ORs) and 95% confidence intervals (CIs) were computed for indicator variables, using a predetermined category level as a reference. While stratified analyses were conducted by the risk classification of HPV types (ie, oncogenic and nononcogenic), we present results from the main analysis that evaluated any anal HPV infection. This was justified because in a polytomous regression model used to test for heterogeneity, we observed no evidence for heterogeneity in the risk factors for oncogenic and nononcogenic infection, with one exception: anal fissure was only associated with oncogenic HPV types (Supplementary Table 1 ). To evaluate the independent determinants of anal HPV infection, risk factors that were significantly associated with infection in the univariate analysis were included in multivariate models. Multivariate analyses stratified by history of anal intercourse were also performed. For all analyses, a P value of <.05 (2-tailed) was considered statistically significant.
Reanalysis of the predictors of anal HPV infection after exclusion of the uncharacterized HPV infections (defined as DEIA-positive and LiPA-negative specimens) did not affect the point estimates substantially nor the interpretation of the results.
RESULTS
Sample Characteristics
Of the 7466 women randomized, 3171 from the control arm attended the 4-year study visit. After exclusion of 188 women who had no history of sexual intercourse and from whom an anal specimen was not collected, 2983 were invited to participate in the present ancillary study. A total of 2112 women (70.8%) provided an anal specimen, and 871 refused. Women who provided an anal specimen were slightly older, less educated, more likely to be currently married, had more pregnancies, and smoked more cigarettes/week than women who refused (data not shown). Women who provided an anal specimen were also younger at sexual debut, reported a greater lifetime number of sex partners, more frequently reported anal intercourse, and less frequently received a diagnosis of irritable bowel syndrome. These 2 groups of women were comparable with respect to smoking status (never/former/current), condom use, and cervical HPV positivity at the 4-year study visit.
Anal HPV Prevalence
After collection of exfoliated cells from the anal canal for HPV DNA testing, samples from 5 women were excluded because the specimen was inadequate and precluded HPV DNA analysis, resulting in 2107 participating women. The overall anal HPV prevalence was 31.6% (95% CI, 29.6-33.6) ( 
HPV Infection Prevalence, by History of Anal Intercourse
Anal HPV prevalence for any type and for most of the oncogenic and nononcogenic types was higher among women with history of anal intercourse ( Table 1 ). The following HPV types were statistically significantly more prevalent among women who reported anal sex: 58, 59, 18, 33, and 16 among oncogenic types and 43, 53, 44, and 70 among nononcogenic types. The percentage of multiple-type infections was significantly higher among women with a history of anal intercourse as compared to those without (21.2% vs 11.2%; P < .0001). Uncharacterized HPV infections were present among both groups (6.6% and 5.3%, respectively).
Risk Factors for Anal HPV Infection
HPV prevalence did not vary by age across our narrow age range. The prevalence of any HPV positivity was 32.8% among women aged 22-23 years, 31.1% among those aged 24-25 years, 29.5% among those aged 26-27 years, and 32.8% among those aged 28-29 years.
In the univariate model, the risk factors associated with any HPV prevalence were the same as those for oncogenic, nononcogenic, and HPV-16 infection (Supplementary Table 1) ; thus, multivariate risk factor analysis was presented using the outcome "any HPV infection." Table 2 shows all independent risk factors for anal HPV infection (any type): lifetime number of sex partners (adjusted OR [aOR], 2.3 [95% CI, 1.7-3.1] for the highest risk category of ≥4 partners), number of anal intercourse partners (aOR, 2.8 [95% CI, 1.7-4.5] for ≥2 partners), and any concurrent cervical HPV infection (measured at the same study visit as anal specimen collection; aOR, 4.8 [95% CI, 3.9-5.9]). Measurements of cervical HPV infection as concurrent (ie, 1-time detection at the same time as anal specimen collection) or persistent (ie, detection 1 year prior to collection of the anal specimen and then again at the study visit when the anal specimen was collected) similarly elevated the odds of anal HPV yet were collinear. This indicates that contemporaneous cervical HPV infection was most important for Abbreviation: CI, confidence interval. a Values were calculated using the denominator of 666, which consists of all women for whom HPV types were characterized, unless otherwise indicated.
b Detection was more frequent among women who reported anal intercourse, compared with those who did not (P < .05).
c Value was calculated using the denominator of 783, which consists of all women in whom any HPV type was detected, regardless of whether it was characterized.
increasing the odds of anal infection, regardless of whether the cervical infection was measured at the preceding study visit.
Multivariate analyses stratified by history of anal intercourse were also conducted (Table 3) . Among women with and women without a history of anal intercourse, the number of Statistically significant findings are in bold.
Abbreviations: CI, confidence interval; OR, odds ratio. a Adjusted for all variables included in the table.
b Includes women with a missing value, those who refused to respond, and those who responded "don't know" for this variable.
c Includes women who did not having missing values for a related variable above yet had a missing value, refused to respond, or responded "don't know" for this variable. Categories that have ≤5 cases were collapsed; subjects who tested positive for an uncharacterized HPV type were included in the negative HPV group.
sex partners and cervical HPV infection each elevated the odds of anal HPV infection; persistent and concurrent cervical HPV infection were similarly associated with anal HPV infection (data not shown). Among women who reported anal sex, those who reported ≥2 lifetime anal sex partners had an increased odds of anal HPV infection (aOR, 1.9 [95% CI, 1.1- 
DISCUSSION
This study provides information on the epidemiology of anal HPV infection among young, sexually active adult women participating in the control arm of the community-based CVT. Anal HPV infection was relatively common: 4% of women had anal HPV-16 infection, 22% had an oncogenic HPV infection, and 32% had any type of anal HPV detected. The main risk factors for anal HPV infection were (1) high number of lifetime sex partners, (2) cervical HPV infection, and (3) anal sex. Among women who reported anal sex, the odds of anal HPV infection increased as the number of anal sex partners increased. Of interest, among women who reported no anal intercourse, anal HPV infection was still common, and anal fissures were an independent determinant of anal HPV infection.
The observed prevalence of anal HPV infection among women in the Costa Rica study appears to be similar to that in the other large study of anal HPV infection, which involves healthy adult women in Hawaii [16] . Restriction of data from the Hawaii cohort to that for women of the ages included in our study (22-29 years) , oncogenic anal HPV prevalence was 21%, and anal HPV16 prevalence was 5% (M. T. Goodman, B. Hernandez, and Y. Shvetsov, personal communication). Given our confirmation of their observed anal HPV prevalence, it seems that the contemporary estimate among generally healthy women for anal HPV-16 infection, the main HPV type implicated in anal cancer, is around 4%-5%. It is important to note that, in our population and, likely, in others, the observed anal HPV prevalence may be somehow inflated, since women who provided an anal specimen were more likely to participate in anal sex practices and to have a higher lifetime number of sexual and anal intercourse partners.
While HPV-16 is responsible for the bulk of anal cancers, it was not the most common type detected among the healthy women. All 25 HPV types tested for in our study were detected as single or multiple infections, in agreement with findings from the Hawaii study [16] . The most prevalent oncogenic types were HPV-51, HPV-52, and HPV-16. Anal infection with certain specific HPV types were more frequently found among women with history of anal intercourse; specifically, HPV types 58, 59, 18, 33, 16, 39, 31, and 51 were at least twice as common among those women, compared with the women who did not report a history of anal intercourse Cervical HPV infection was a strong risk factor for anal HPV infection: anal HPV prevalence was significantly higher among women with concurrent cervical infection than among women who were negative for cervical HPV (19.7% vs 11.9%; P < .001). Of interest, the ORs for concurrent cervical HPV detection (4.8) and persistent cervical HPV detection (5.1) were similar. We interpret this to mean that having cervical HPV at the time of anal specimen collection was most important; having the cervical infection detected prior to that visit and again concurrently did not additionally increase risk of anal HPV detection. Other risk factors that elevated the odds of anal HPV infection were sexual in nature and included history of anal intercourse and more general sexual exposures (ie, lifetime number of sex partners), factors that have been previously associated with high prevalence of anal HPV infection in women [13, 16] and men [15, 24] . Other routes for introduction of HPV infection in the anal canal have been proposed (ie, autoinoculation or nonpenetrative sexual behaviors) [11, 16, 25] . Our data support this notion: among women who did not report anal sex, anal fissures that could abrade the anal epithelium significantly increased the odds of anal HPV infection.
The advantages of this study include a large sample size that allowed for the analysis of several important risk factors and for stratified analysis based on anal sexual behavior. Although the present study represents the largest group of young adult women tested for anal HPV infection and sampling was based on a population census, women may not be fully representative of the general population because they were participants in a clinical HPV vaccine trial in which several exclusion criteria applied. Additionally, the current lack of longitudinal data meant we could only report on prevalent anal HPV infection and not on incident or persistent anal HPV infection; ongoing serial anal specimen collection will address this limitation in future reports.
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